Clinigence Holdings, Inc. Logo

Clinigence Holdings, Inc.

CLNH

(0.8)
Stock Price

6,40 USD

-76.76% ROA

2.58% ROE

-2313.95x PER

Market Cap.

0,00 USD

5.33% DER

0% Yield

-72.74% NPM

Clinigence Holdings, Inc. Stock Analysis

Clinigence Holdings, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Clinigence Holdings, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (14%), which means it has a small amount of debt compared to the ownership it holds

2 ROE

The stock's ROE falls within an average range (2.58%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

3 ROA

The stock's ROA (-76.76%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

4 PBV

The stock's elevated P/BV ratio (420.96x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

5 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

6 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

7 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Clinigence Holdings, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Clinigence Holdings, Inc. Technical Stock Analysis
# Analysis Recommendation

Clinigence Holdings, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Clinigence Holdings, Inc. Revenue
Year Revenue Growth
2008 0
2009 173.011 100%
2010 874.774 80.22%
2011 1.783.904 50.96%
2012 1.593.886 -11.92%
2013 1.461.183 -9.08%
2014 1.068.617 -36.74%
2015 474.679 -125.12%
2016 0 0%
2017 23.166 100%
2018 60.224 61.53%
2019 1.366.419 95.59%
2020 1.586 -86109.4%
2021 75.172 97.89%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Clinigence Holdings, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2008 0
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 768.103 100%
2020 557 -137800%
2021 -833.316 100.07%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Clinigence Holdings, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2008 196.589
2009 861.512 77.18%
2010 1.829.401 52.91%
2011 0 0%
2012 2.383.568 100%
2013 1.692.556 -40.83%
2014 1.383.646 -22.33%
2015 965.609 -43.29%
2016 448.595 -115.25%
2017 1.813.624 75.27%
2018 1.163.766 -55.84%
2019 3.667.178 68.27%
2020 3.251 -112701.54%
2021 -31.752.703 100.01%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Clinigence Holdings, Inc. EBITDA
Year EBITDA Growth
2008 359.701
2009 192.284 -87.07%
2010 -339.142 156.7%
2011 -645.935 47.5%
2012 -1.521.202 57.54%
2013 311.688 588.05%
2014 -669.243 146.57%
2015 133.324 601.97%
2016 -7.429.189 101.79%
2017 1.876.438 495.92%
2018 -1.082.578 273.33%
2019 -6.852.547 84.2%
2020 9.199 74592.3%
2021 18.717.276 99.95%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Clinigence Holdings, Inc. Gross Profit
Year Gross Profit Growth
2008 0
2009 125.553 100%
2010 483.188 74.02%
2011 1.019.155 52.59%
2012 810.381 -25.76%
2013 965.175 16.04%
2014 603.280 -59.99%
2015 466.628 -29.28%
2016 0 0%
2017 -7.315 100%
2018 29.075 125.16%
2019 535.976 94.58%
2020 676 -79186.39%
2021 -40.490.585 100%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Clinigence Holdings, Inc. Net Profit
Year Net Profit Growth
2008 403.393
2009 445.759 9.5%
2010 158.137 -181.88%
2011 -383.393 141.25%
2012 -1.623.895 76.39%
2013 250.489 748.29%
2014 -684.342 136.6%
2015 83.809 916.55%
2016 -7.432.241 101.13%
2017 582.062 1376.88%
2018 -2.814.245 120.68%
2019 -7.116.520 60.45%
2020 -5.650 -125856.11%
2021 36.243.508 100.02%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Clinigence Holdings, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2008 9
2009 10 0%
2010 3 -200%
2011 -8 137.5%
2012 -34 75.76%
2013 5 760%
2014 -13 138.46%
2015 1 1400%
2016 -94 101.08%
2017 3 3200%
2018 -10 133.33%
2019 -2 -800%
2020 0 0%
2021 1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Clinigence Holdings, Inc. Free Cashflow
Year Free Cashflow Growth
2008 119.226
2009 -110.593 207.81%
2010 -1.642.833 93.27%
2011 -678.527 -142.12%
2012 -526.744 -28.82%
2013 -183.151 -187.6%
2014 163.779 211.83%
2015 43.110 -279.91%
2016 -274.223 115.72%
2017 -714.623 61.63%
2018 -765.471 6.64%
2019 -4.124.580 81.44%
2020 -1.474.575 -179.71%
2021 3.964.015 137.2%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Clinigence Holdings, Inc. Operating Cashflow
Year Operating Cashflow Growth
2008 121.090
2009 -110.593 209.49%
2010 -1.637.145 93.24%
2011 -659.136 -148.38%
2012 -518.687 -27.08%
2013 -183.151 -183.2%
2014 165.805 210.46%
2015 44.907 -269.22%
2016 -274.223 116.38%
2017 -714.623 61.63%
2018 -765.471 6.64%
2019 -4.040.578 81.06%
2020 -1.475.075 -173.92%
2021 3.964.015 137.21%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Clinigence Holdings, Inc. Capital Expenditure
Year Capital Expenditure Growth
2008 1.864
2009 0 0%
2010 5.688 100%
2011 19.391 70.67%
2012 8.057 -140.67%
2013 0 0%
2014 2.026 100%
2015 1.797 -12.74%
2016 0 0%
2017 0 0%
2018 0 0%
2019 84.002 100%
2020 -500 16900.4%
2021 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Clinigence Holdings, Inc. Equity
Year Equity Growth
2008 953.884
2009 1.787.617 46.64%
2010 1.985.171 9.95%
2011 1.602.593 -23.87%
2012 305.698 -424.24%
2013 556.187 45.04%
2014 -4.491 12484.48%
2015 1.561.316 100.29%
2016 -5.869.425 126.6%
2017 2.368.975 347.76%
2018 1.233.019 -92.13%
2019 1.858.433 33.65%
2020 -1.133.795 263.91%
2021 75.138.622 101.51%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Clinigence Holdings, Inc. Assets
Year Assets Growth
2008 1.450.176
2009 1.994.608 27.3%
2010 2.336.788 14.64%
2011 1.891.178 -23.56%
2012 745.919 -153.54%
2013 1.071.342 30.38%
2014 280.786 -281.55%
2015 7.637.996 96.32%
2016 510.835 -1395.2%
2017 3.328.755 84.65%
2018 2.618.466 -27.13%
2019 6.692.504 60.87%
2020 169.447 -3849.61%
2021 85.733.528 99.8%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Clinigence Holdings, Inc. Liabilities
Year Liabilities Growth
2008 496.292
2009 206.991 -139.77%
2010 351.617 41.13%
2011 288.585 -21.84%
2012 440.221 34.45%
2013 515.155 14.55%
2014 285.277 -80.58%
2015 6.076.680 95.31%
2016 6.380.260 4.76%
2017 959.780 -564.76%
2018 1.385.447 30.72%
2019 4.834.071 71.34%
2020 1.303.652 -270.81%
2021 10.594.906 87.7%

Clinigence Holdings, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0
Price to Earning Ratio
-2313.95x
Price To Sales Ratio
0x
POCF Ratio
-4718.49
PFCF Ratio
0
Price to Book Ratio
420.97
EV to Sales
-0.6
EV Over EBITDA
0.95
EV to Operating CashFlow
1.69
EV to FreeCashFlow
1.69
Earnings Yield
-0
FreeCashFlow Yield
0
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0.03
Graham NetNet
0

Income Statement Metrics

Net Income per Share
-0
Income Quality
0.49
ROE
0.03
Return On Assets
-0.16
Return On Capital Employed
-0.15
Net Income per EBT
1.08
EBT Per Ebit
1.07
Ebit per Revenue
-0.63
Effective Tax Rate
-0.08

Margins

Sales, General, & Administrative to Revenue
0.65
Research & Developement to Revenue
0.02
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.22
Operating Profit Margin
-0.63
Pretax Profit Margin
-0.67
Net Profit Margin
-0.73

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0
Free CashFlow per Share
-0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-0.16
Return on Tangible Assets
-0.77
Days Sales Outstanding
12.57
Days Payables Outstanding
0
Days of Inventory on Hand
0.01
Receivables Turnover
29.03
Payables Turnover
0
Inventory Turnover
36617.5
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,02
Tangible Book Value per Share
0
Shareholders Equity per Share
0.02
Interest Debt per Share
0
Debt to Equity
0.05
Debt to Assets
0.05
Net Debt to EBITDA
0.95
Current Ratio
2.05
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0.05
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.79
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0.2
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Clinigence Holdings, Inc. Dividends
Year Dividends Growth

Clinigence Holdings, Inc. Profile

About Clinigence Holdings, Inc.

Clinigence Holdings, Inc. provides health care services. It offers medicare management, performance metrics, cost improvement and performance improvement plans, and health management services. The company was incorporated in 2014 and is based in Fort Lauderdale, Florida.

CEO
Dr. Warren Hosseinion
Employee
12
Address
55 Ivan Allen Jr. Boulevard NW
Atlanta, 33304

Clinigence Holdings, Inc. Executives & BODs

Clinigence Holdings, Inc. Executives & BODs
# Name Age

Clinigence Holdings, Inc. Competitors